$1.55 Billion is the total value of Camber Capital Management LP's 45 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVA | NUVASIVE INC | $59,521,000 | +12.2% | 1,100,000 | 0.0% | 3.85% | -15.4% | |
| OFIX | ORTHOFIX INTL N V | $58,815,000 | +16.2% | 1,500,000 | 0.0% | 3.80% | -12.4% | |
| MASI | MASIMO CORP | $41,510,000 | +7.7% | 1,000,000 | 0.0% | 2.68% | -18.8% | |
| UAM | UNIVERSAL AMERN CORP NEW | $41,125,000 | +2.3% | 5,875,000 | 0.0% | 2.66% | -22.8% | |
| DRRX | DURECT CORP | $13,260,000 | +13.3% | 6,000,000 | 0.0% | 0.86% | -14.5% | |
| OSUR | ORASURE TECHNOLOGIES INC | $12,880,000 | +45.0% | 2,000,000 | 0.0% | 0.83% | +9.3% | |
| BIOS | BIOSCRIP INC | $10,500,000 | -6.4% | 6,000,000 | 0.0% | 0.68% | -29.3% | |
| INNOCOLL AG | $9,222,000 | -34.5% | 1,111,111 | 0.0% | 0.60% | -50.6% | ||
| CATB | CATABASIS PHARMACEUTICALS IN | $7,930,000 | -2.0% | 1,000,000 | 0.0% | 0.51% | -26.1% | |
| PROTALIX BIOTHERAPEUTICS INC.note 4.500% 9/1 | $6,075,000 | -1.7% | 9,000,000 | 0.0% | 0.39% | -25.8% | ||
| EPRSQ | EPIRUS BIOPHARMACEUTICALS INC | $5,709,000 | -30.1% | 1,847,500 | 0.0% | 0.37% | -47.3% | |
| BIOL | BIOLASE INC | $4,485,000 | -6.5% | 5,332,394 | 0.0% | 0.29% | -29.4% | |
| UNIS | UNILIFE CORP NEW | $1,362,000 | -49.5% | 2,750,000 | 0.0% | 0.09% | -61.9% | |
| CRDC | CARDICA INC | $1,298,000 | -46.2% | 8,374,846 | 0.0% | 0.08% | -59.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.